From 1 November 2024, the following new and amended pathology items will be listed on the Medicare Benefits Schedule, including:

• New item 66829 will be introduced for Brain Natriuretic Peptide (BNP) or N-Terminal-pro Brain Natriuretic Peptide (NT-proBNP) testing to aid in the diagnosis of patients with suspected heart failure;
• New items (73813 and 73825) will be introduced for point of care testing for sexually transmissible infections in remote areas;
• Amendment to item 73343 for 17p deletion testing of patients with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) to remove specification of test methodology;
• Amendment to items 73420 and 73421 for Rhesus D non-invasive prenatal testing (NIPT) of non-alloimmunised patients; and
• Amendment of item 73451 for reproductive carrier risk testing for cystic fibrosis, spinal muscular atrophy and fragile X syndrome.

Further information and guidance can be found in the below factsheets:

Fact Sheet	PDF and Word versions
Quantification of B-type natriuretic peptide (BNP) or N-Terminal-pro brain natriuretic peptide (NT-proBNP) testing to aid in the diagnosis of patients with suspected heart failure in non-hospital settings (Last updated: 14 October 2024)	Word Version - Brain Natriuretic Peptide or N-Terminal-pro Brain Natriuretic Peptide to aid in the diagnosis of patients with suspected heart failure – new item 66829 (Word 123 KB) PDF Version - Brain Natriuretic Peptide or N-Terminal-pro Brain Natriuretic Peptide to aid in the diagnosis of patients with suspected heart failure – new item 66829 (PDF 152 KB)
New Medicare Benefits Schedule (MBS) items for point of care (PoC) testing for detection of sexually transmitted infections (STIs) in remote areas (Last updated: 14 October 2024)	Word Version - New Medicare Benefits Schedule items for point of care testing for detection of sexually transmitted infections in remote areas (Word 128 KB) PDF Version - New Medicare Benefits Schedule items for point of care testing for detection of sexually transmitted infections in remote areas (PDF 161 KB)
Amendment to item 73343 for 17p deletion testing of lymphocytic lymphoma patients to remove reference to test methodologies (Last updated: 14 October 2024)	Word Version - Amendment of descriptor for 73343 for 17p deletion testing of patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma (Word 122 KB) PDF Version - Amendment of descriptor for 73343 for 17p deletion testing of patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma (PDF 146 KB)
Changes to the Medicare Benefits Schedule (MBS) items 73420 and 73421 for Rhesus D non-invasive prenatal testing (NIPT) of non-alloimmunised patients (Last updated: 14 October 2024)	Word Version - Amendment of items 73420 and 73421 for Rhesus D non-invasive prenatal testing of non-alloimmunised patients (Word 125 KB) PDF Version - Amendment of items 73420 and 73421 for Rhesus D non-invasive prenatal testing of non-alloimmunised patients (PDF 174 KB)
Amendment of MBS item 73451 for reproductive carrier testing for cystic fibrosis (CF), spinal muscular atrophy (SMA) and fragile X (FXS) syndrome (Last updated: 14 October 2024)	Word Version - Amendment of MBS item 73451 for reproductive carrier testing for cystic fibrosis, spinal muscular atrophy and fragile X syndrome (Word 122 KB) PDF Version - Amendment of MBS item 73451 for reproductive carrier testing for cystic fibrosis, spinal muscular atrophy and fragile X syndrome (PDF 148 KB)